Professional COVID-19 Antibody Rapid Screening Test

  • Results in 15 minutes
  • Optimal for testing between 18 and 35 days after initial exposure
  • Test kits from just £6 per test – for use by medical professionals

These are professional test kits using a single drop of blood to determine the levels of antibodies (IgM and IgG) using a rapid test device.

These LFIA (Lateral Flow ImmunoAssay) screening kits have been approved for sale in the UK by the MHRA and carry CE certification for use across Europe.

The test itself is carried out using a small lancet similar to that used for a diabetes finger-prick test.  It should be carried out under the supervision of a health professional but it is a quick and simple process and we can arrange supervision by a trained nurse via a Zoom session if required.

The results are shown by two lines on the test device – similar to reading a pregnancy test result – one for IgM (the antibody initially created by the body to determine the best way to fight the infection) and IgG (the “mass-produced” antibody used to fight and kill the virus and clear the infection).

Unlike AntiGen testing, which looks for the DNA of the virus in the initial stages of infection, AntiBody testing looks for the bodies’ response to the virus, so is more effective in the latter stages of infection when the levels of the virus have declined (so more difficult to detect using AntiGen testing) and the Antibody levels have risen.

Note that the MHRA’s role in approving the sale of a device does not include their evaluation of the voracity of a product.

Accuracy, Sensitivity and Specificity to Covid-19 Antibodies IgG & IgM

Sensitivity: IgG 100%, IgM 95.5%               Specificity: IgG 98%, IgM 100%                Overall Accuracy: IgG 98.7%, IgM 98.6%

Box of 25 tests with wipes & lancets
25x Lateral Flow Test Devices, 25x Lancets, 25x sterile wipes, 25x pipettes, 1 x bottle buffer solution

from £7 per test (ex VAT)

(pricing decreases with quantity)

Add to Basket

Bulk box of 40 tests
40x Lateral Flow Test Devices, 40x pipettes,
1 x bottle buffer solution (NO lancets/wipes)

from £6 per test (ex VAT)

(pricing decreases with quantity)

Add to Basket

Limitations of test:

  1. The Assay Procedure and the Test Result Interpretation must be followed closely when testing the presence of antibodies to 2019-nCoV virus in serum or plasma from individual subjects. Failure to follow the procedure may give inaccurate results.
  2. The 2019-nCoV IgG/IgM Rapid Test is limited to the qualitative detection of antibodies to 2019- nCoV virus in human whole blood, serum or plasma. The intensity of the test band does not have linear correlation with the antibody titer in the specimen.
  3. The 2019-nCoV IgG/IgM Rapid Test can not be used to differentiate if the infection is primary or secondary. No information of 2019-nCoV serotypes can be provided with this test.
  4. A negative or non-reactive result for an individual subject indicates absence of detectable 2019- nCoV virus antibodies. A negative or non-reactive test result does not preclude the possibility of exposure to or infection with 2019-nCoV virus.
  5. A negative or non-reactive result can occur if the quantity of the 2019-nCoV virus antibodies present in the specimen is below the detection limits of the assay, or the antibodies that are detected are not present during the stage of disease in which a sample is collected.
  6. Some specimens containing unusually high titer of heterophile antibodies or rheumatoid factor may affect expected results.
  7. If the symptom persists, while the result from 2019-nCoV IgG/IgM Rapid Test is negative or non-reactive result, it is recommended to re-sample the patient few days later or test with an alternative test device.
  8. The results obtained with this test should only be interpreted in conjunction with other diagnostic procedures and clinical findings.